Determining Heart Attack in the ER
The research team decided to conduct a clinical trial to assess the new technique's effectiveness in determining whether a patient has had a heart attack. They enrolled 1,320 patients who visited the emergency department with suspected acute myocardial infarction (MI) and applied the high-sensitivity cardiac troponin T 1-hour algorithm to blood samples.
Acute MI is a common cause of death and disability around the world. Early diagnosis of the condition is critical for treatment and survival. Cardiac troponins (T and I) are currently the gold standard for definitive acute MI diagnosis due to their high sensitivity and specificity for detection of myocardial cell injury. However, troponin is undetectable by current tests in peripheral blood within 3 to 4 hours after onset of chest pain in acute MI.
"Introducing the high-sensitivity cardiac troponin T 1-hour algorithm into clinical practice would represent a profound change and it is therefore important to determine if it works in a large patient group," explains the study's lead author Dr. Tobias Reichlin, Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.
With the 1-hour algorithm, Dr. Reichlin and colleagues were able to determine that 786 (60 percent) of patients did not have an acute MI ("rule out"), 216 (16 percent) were "rule in" and 318 (24 percent) were to be observed because results were not conclusive.
"This rapid strategy incorporating high-sensitivity cardiac troponin T baseline values and absolute changes after the first hour substantially accelerates the management of patients with suspected acute MI by allowing safe rule-out as well as accurate rule-in of acute MI in 3 out of 4 patients," Dr. Reichlin's team concludes. The findings are reported in CMAJ (Canadian Medical Association Journal).
Source: Canadian Medical Association Journal
Image Credit: Google Images
Published on : Thu, 16 Apr 2015
Always in sight, always in mind Features Mindray believes the best way to predict the future is to create it. The revolutionary BeneVision N22/N19 is designed to optimize user experience by satisfying all your clinical demands. With visionary-stimulating...
The fully-automated Accelerate Pheno™ system is designed to eliminate the lengthy culture and sample preparation steps required for most sample types prior to antimicrobial susceptibility testing. In addition, it hosts proprietary molecular identification...
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery. All blood-contact surfaces of the NovaPort cannulas are coated with the bio-...